DXd-THP achieved a pCR rate of 67.3% versus 56.3% with ddAC-THP, "the highest reported pCR rate in HER2-positive early breast ...

Daiichi and Merck saw the highest ORR—57.1%—in patients who received the top dose of R-DXd. Yet the drugmakers have opted to take the middle 5.6-mg/kg dose into the phase 3 part of the trial. The ORR ...

Mayo Clinic researchers have discovered a key reason why certain breast cancers might not respond to an important new class ...

Daiichi Sankyo Company ((DSKYF)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, ...

Two phase 3 trials suggest that the antibody drug conjugate led to significantly improved outcomes in both the neoadjuvant ...

Patients with advanced triple negative breast cancer ineligible for immunotherapy may overcome their typically poor prognosis ...

Dato-DXd improved outcomes over chemotherapy in patients with locally recurrent inoperable or metastatic TNBC who were ineligible for immunotherapy.

Daiichi Sankyo Company (($DSKYF)) announced an update on their ongoing clinical study. Study Overview: Daiichi Sankyo Company, in collaboration ...

R-DXd showed a 50.5% objective response rate in platinum-resistant ovarian cancer, with a 5.6 mg/kg dose deemed optimal for further study. The safety profile was manageable, with 93.5% experiencing ...

Click to share on X (Opens in new window) X Click to share on Facebook (Opens in new window) Facebook After a notable break between seasons, the High School DxD anime made its surprising return last ...

Dato-DXd showed a 43% reduction in disease progression risk and a 21% reduction in death risk compared to chemotherapy in TNBC patients ineligible for immunotherapy. The TROPION-Breast02 trial ...